|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Finally, we showed that cells formed tumors when re-introduced into mice, providing an authentic in vitro-in vivo preclinical model of a subtype of prostate cancer with a hypermutator phenotype and an SPOP mutation.
|
24998678 |
2014 |
|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
IQGAP2 (5q13.3) genomic alterations were observed in SPOP-marked PCs and co-occurred with deletion in the RN7SK (16p12.2), SNORA50A (16q21), and SNORA50C (17q23.3) genes; the co-occurrence associated with reductions in DFS (P=4.14e-4).
|
30428404 |
2019 |
|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Importantly, cancer-derived mutations in SPOP or at the Nanog-degron (S68Y) disrupt SPOP-mediated destruction of Nanog, leading to elevated cancer stem cell traits and PrCa progression.
|
30595538 |
2019 |
|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation.
|
27780719 |
2017 |
|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We show that recurrent PC-driver mutations in speckle-type POZ protein (SPOP) stabilize the TRIM24 protein, which promotes proliferation under low androgen conditions.
|
27238081 |
2016 |
|
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
These results demonstrate that FASN is a crucial mediator of SPOP-induced inhibition of PCa cell growth.
|
30955223 |
2019 |
|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These studies provide a possible explanation for the role of SPOP mutations in PC, and highlight the potential of SRC-3 as a therapeutic target in PC.
|
23559371 |
2013 |
|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
However, how SPOP mutations contribute to prostate cancer pathogenesis remains poorly understood.
|
28448495 |
2017 |
|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
|
Malignant neoplasm of prostate
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
TRIM24 and AR coactivated gene signature of SPOP-mutant PCa is similarly activated in human PCa with high TRIM28 expression.
|
30479348 |
2018 |
|
Malignant neoplasm of prostate
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
SPOP was found to be strongly down-regulated in PCa (median=0.24; range=0.04-9.98) and its expression was associated with both, biochemical (p=0.003) and clinical progression free survival (p=0.023), the very low SPOP expression levels being associated to the worst prognosis.
|
25204806 |
2014 |
|
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Using next-generation sequencing to analyze the mutations in PC, the main molecular PC subtypes were identified, which depended on the presence of fusion genes and FOXA1, CHD1, and SPOP point mutations; other driver mutations responsible for the progression of PC subclones were also characterized.
|
28659719 |
2017 |
|
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.
|
25274033 |
2014 |
|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
SPOP is mutated in 4.6% to 14.4% of patients with prostate cancer across different ethnic and demographic backgrounds.
|
24563616 |
2014 |
|
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
Altogether, we have revealed a novel mechanism for SPOP in suppressing prostate cancer and provided evidence to show SPOP has dual functions in prostate cancer and CCRC.
|
30237511 |
2019 |
|
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
CTD_human |
Thus, SPOP mutations may define a new molecular subtype of prostate cancer.
|
22610119 |
2012 |
|
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our data show that resistance to BET inhibitors in SPOP-mutant prostate cancer can be overcome by combination with AKT inhibitors and further support the evaluation of SPOP mutations as biomarkers to guide BET-inhibitor-oriented therapy in patients with prostate cancer.
|
28805822 |
2017 |
|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In summary, we found no evidence that ERG is an effector of SPOP mutation in human prostate cancer or mouse models.
|
29202479 |
2018 |
|
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our structural and biophysical data confirm the suggested loss-of-function in prostate cancer-associated SPOP mutants and provide mechanistic explanation.
|
31026449 |
2019 |
|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
SPOP mutations contribute to prostate cancer development by altering the steady-state levels of key components in the androgen-signaling pathway.
|
25058385 |
2014 |
|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to compare the frequency of ERG rearrangement, PTEN deletion, SPINK1 overexpression, and SPOP mutation in prostate cancer in African American and Caucasian men.
|
25056375 |
2014 |
|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Class-1 activating mutations originate in early prostate cancer without alterations in ETS or SPOP, selectively recur within the wing-2 region of the DNA-binding forkhead domain, enable enhanced chromatin mobility and binding frequency, and strongly transactivate a luminal androgen-receptor program of prostate oncogenesis.
|
31243372 |
2019 |
|
Malignant neoplasm of prostate
|
0.700 |
Biomarker
|
disease |
BEFREE |
SPOP has been shown to be responsible for oncogene SRC-3 ubiquitination and proteolysis in prostate cancers.
|
29461588 |
2018 |
|
Malignant neoplasm of prostate
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Further studies with increased sample size are needed to validate the clinicopathological significance of these SPOP mutations in AA-PCa.
|
24994784 |
2015 |